Daniel Montano photo

BIOTECH, HEALTHCARE, TECHNOLOGY

Daniel Montano

CEO,

Zhittya Genesis Medicine, Inc.

  • CEO at Zhittya Genesis Medicine Inc.
  • Dedicated to Advance Biotechnology Breakthroughs
  • 30 Years Financial Industry Expertise

About Daniel

Dan Montano started at the Los Angeles Stock Exchange in 1968 as a floor broker. Over the next 30 years, he managed thousands of stockbrokers as CEO of several securities firms. As an investment banker, Mr. Montano handled the IPO's of over 100 companies from 1968 until 1998. During that time, he also assisted in starting almost 100 new companies to advance new technologies. In 1998, Mr. Montano left investment banking and dedicated himself to advance biotechnology breakthroughs. Presently, he is CEO of Zhittya Genesis Medicine Inc., a bio-pharmaceutical company developing drug treatments for heart disease, strokes, Parkinson's disease, Alzheimer's, and more.

Daniel's Videos

A presentation discussing the possibility of using Intranasally-delivered FGF-1 to treat Parkinson's Disease. This presentation will be using data and information from our most recent medical research study conducted in humans in May 2022.
Human FGF-1 is a potent growth factor that has been shown to stimulate the growth of new blood vessels, as well as new neurons, in animal models of Parkinson's disease and other brain disorders. In this talk, this previous research will be reviewed, as well as the presentation of late-breaking results from a just completed first human study examining the intranasal delivery of FGF-1 to subjects with Parkinson's disease.

Zhittya Genesis Medicine, Inc., is developing novel pharmaceuticals that have the potential to treat and reverse diseases that account for more than 50% of all adult deaths, worldwide. In FDA-authorized clinical trials these drugs have shown remarkable success in reversing severe coronary artery disease and healing chronic diabetic foot ulcers. New clinical trials are planned in the coming year to treat patients with Parkinson's disease, ALS (Lou Gehrig's disease), multiple sclerosis, chronic stroke, and Alzheimer's disease. A very attractive Pre-IPO investment is now being offered to suitable investors to help fund the upcoming IPO, which has a firm commitment from a highly regarded securities firm and will take place in 5-6 months.

Zhittya Genesis Medicine, Inc., is developing novel pharmaceuticals that have the potential to treat and reverse diseases that account for more than 50% of all adult deaths, worldwide. In FDA-authorized clinical trials these drugs have shown remarkable success in reversing severe coronary artery disease and healing chronic diabetic foot ulcers. New clinical trials are planned in the coming year to treat patients with Parkinson's disease, ALS (Lou Gehrig's disease), multiple sclerosis, chronic stroke, and Alzheimer's disease. A very attractive Pre-IPO investment is now being offered to suitable investors to help fund the upcoming IPO, which has a firm commitment from a highly regarded securities firm and will take place in 5-6 months.
Live Now

Powerful Investing & Trading Strategies

March 19 - 21, 2024